ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC Trading Update and Notice of Interim Results (2507U)

23/10/2017 7:00am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 2507U

Omega Diagnostics Group PLC

23 October 2017

Omega Diagnostics Group PLC

("Omega" or "the Company")

Trading Update and Notice of Interim Results

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following trading update for the six months to 30 September 2017, in advance of releasing its interim results on Thursday 14 December 2017.

Financial update

Turnover is expected to be GBP7.11m, in line with last year's first half in constant currency terms and 4% ahead of last year's result (2016: GBP6.83m) on an actual basis. This reflects the weakening of sterling in the post-Brexit environment. Profit before tax (before share-based payments, IFRS-related discount unwinds and amortisation of intangible assets) is in line with expectation at the half-year stage.

Segmental revenues are expected to be as follows:

 
                                 Revenue to       Revenue to                 % increase                % increase 
                               30 September     30 September                                                 CER* 
                                       2017             2016 
 Food Intolerance                  GBP4.13m         GBP3.84m                       + 8%                      + 4% 
 Allergy/Autoimmune                GBP1.67m         GBP1.76m                       - 5%                     - 11% 
 Infectious Disease/Other          GBP1.31m         GBP1.23m                       + 7%                      + 5% 
 TOTAL                             GBP7.11m         GBP6.83m                       + 4%                      + 1% 
 

* Constant exchange rate ("CER") numbers have been restated to remove the impact of foreign exchange movements in the year by restating the performance for the six months ended 30 September 2017 using the exchange rates during the prior period.

Core business update

Food Intolerance

We continue to see strong growth in North America with our microarray-based FoodPrint(R) test. As noted below, North America is a priority market for us and we are focusing resource more closely into this market. With regard to the self-test version of Food Detective(R), the Company was able to successfully complete the actions requested of it by Lloyds Register Quality Assurance ("LRQA") within the agreed timescale and we are awaiting LRQA's final review outcome.

Allergy/Autoimmune

Revenue in the first half of the current financial year declined by 8.5% in our German domestic business, compared to the previous period. A significant amount of above-average rainfall in July was a contributing factor but we are expecting a better performance in the second half of the year. The reduction in euro-denominated revenue was mitigated by the weakening in the pound/euro exchange rate compared to last year.

Infectious Disease

This segment has started to benefit from initial sales of the VISITECT(R) range of Malaria tests manufactured at the facility in Pune, India. A small percentage increase in revenue in actual terms has been positively impacted by the weaker position of sterling, as noted above.

Accelerated growth strategy

As announced in July, the Company was successful in raising funds from two sources:

   --     GBP3.3 million (before expenses) from a placing and open offer 

-- EUR0.8 million (before rent deposit) from the sale and leaseback of its German manufacturing facility

These funds were raised to enable the Company to exploit opportunities which it has identified to accelerate growth.

Increase FoodPrint(R) traction in the USA

As reported on 16 October 2017, the Company has signed a supply agreement with a new partner in the US, bringing the number of partners that the Company is currently working with in the US to three. We continue to believe that the US market represents a key driver for growth in what is the world's largest market for food sensitivity testing.

Allersys(R) product range

We remain on plan to increase the number of CE-Marked allergens that have been developed for use on the IDS instrument to 50-60 allergens by the end of the current financial year. We have had two positive meetings recently with Immunodiagnostics Systems ("IDS") and, subject to finalising a global distribution agreement, we are now confident that we can commercialise our range of products within the current financial year on terms which are beneficial to both parties.

Visitect(R) CD4

We have successfully manufactured bulk components for three validation batches of Visitect(R)CD4 which have passed QC testing at external sites and have now been assembled into devices. The first two batches of assembled devices have passed final QC testing with external testing. A third batch will begin external testing imminently. We have started using these validation batches to verify performance and this programme of testing is about 50% complete. External performance evaluations are underway at two UK hospital sites and we expect these to be completed within the next few weeks. The external performance evaluation in India is now complete and the data is being fully analysed with performance as expected on an initial review of the data. We therefore remain confident in our ability to CE-Mark the test before the end of the calendar year.

Outlook

We have made significant progress on a number of key objectives including:

   --     progress with validating and verifying the performance of Visitect(R) CD4 
   --     increasing our presence in the North American market for food sensitivity testing 
   --     progress with the commercialisation plan for our panel of Allersys(R) reagents 
   --     increasing traction with Visitect(R) Malaria sales 

Trading in the first half of the current financial year was in line with the comparative period in the prior year on a like-for-like basis. We expect a stronger second half and the outturn for the year remains dependent on one or more of the objectives outlined above delivering a material contribution to our results.

David Evans, Chairman of Omega commented: "We continue to advance as a Company in all our key areas and the outlook over the next twelve to eighteen months remains positive - the shorter term is dominated by factors not wholly within our control. We continue to be enthusiastic about prospects for Omega and we hope to announce further progress later in the year.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
 Omega Diagnostics Group PLC                                    Tel: 01259 763 030 
 David Evans, Chairman                                    www.omegadiagnostics.com 
  Andrew Shepherd, Chief Executive 
 Kieron Harbinson, Group Finance 
  Director 
 
 
 finnCap Ltd                                                    Tel: 020 7220 0500 
 Geoff Nash/James Thompson (Corporate 
  Finance) 
 Mia Gardner (Corporate Broking) 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Cawthorne                                               Mob: 07584 391 303 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFFEISLIFID

(END) Dow Jones Newswires

October 23, 2017 02:00 ET (06:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock